Redmile Group, LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), Redmile Group, LLC reported 34 stock positions worth $1.4 billion. Its top holding was Scholar Rock (SRRK) at 16.9% of the portfolio, followed by Krystal Biotech (KRYS, 12.3%) and Nurix Therapeutics (NRIX, 11.3%). Compared with Q3 2025, it opened 3 new positions, sold out of 9, added to 11 and reduced 10. The biggest buy was Nurix Therapeutics (NRIX, shares +120%) and the biggest sale Zymeworks (ZYME, shares −87%).
- Most Recent 13F
- Q2 2026
- Location
- LARKSPUR, CA
- CIK
- 0001425738
- Portfolio Value
- $1.4B (Q4 2025)
- SEC Filing
- 0001104659-26-016433 ↗ filed Feb 17, 2026
Holdings Value
Holdings 34 stocks · $1.4B
| SRRK Scholar Rock Holding Corp. | 16.94% | 5,220,846 | $230.0M | Add +33.7% |
| KRYS Krystal Biotech Inc. | 12.30% | 677,705 | $167.1M | Add +2.5% |
| NRIX Nurix Therapeutics Inc. | 11.31% | 8,093,908 | $153.5M | Add +120.0% |
| STOK Stoke Therapeutics Inc. | 9.43% | 4,034,070 | $128.0M | Reduce -3.4% |
| IMNM Immunome Inc. | 9.05% | 5,718,385 | $122.8M | Add +13.8% |
| RGNX Regenxbio Inc. | 4.63% | 4,368,804 | $62.9M | Reduce -6.9% |
| ADCT Adc Therapeutics SA | 4.07% | 15,666,731 | $55.3M | No change |
| COGT Cogent Biosciences Inc. | 3.76% | 1,437,918 | $51.1M | Reduce -34.9% |
| ANNX Annexon Inc. | 3.72% | 10,050,644 | $50.5M | Add +59.5% |
| BEAM Beam Therapeutics Inc. | 2.62% | 1,285,859 | $35.6M | Reduce -7.3% |
| NGNE Neurogene Inc. | 2.21% | 1,459,599 | $30.1M | Add +12.4% |
| RAPT Rapt Therapeutics Inc. | 2.21% | 885,927 | $30.0M | Add +60.3% |
| ABSI Absci Corp. | 2.12% | 8,253,316 | $28.8M | No change |
| NUVB Nuvation Bio Inc. | 2.09% | 3,163,256 | $28.3M | Add +4.4% |
| IDYA Ideaya Biosciences Inc. | 1.89% | 742,017 | $25.7M | No change |
| STTK Shattuck Labs Inc. | 1.49% | 5,539,724 | $20.2M | No change |
| SLN Silence Therapeutics PLC-ADR | 0.97% | 2,164,777 | $13.2M | No change |
| ZYME Zymeworks Inc. | 0.95% | 491,654 | $12.9M | Reduce -86.7% |
| FATE Fate Therapeutics Inc. | 0.93% | 12,872,946 | $12.6M | No change |
| REPL Replimune Group Inc. | 0.79% | 1,099,756 | $10.7M | Add +105.3% |
| DBVT DBV Technologies SA-Spon ADR | 0.78% | 549,840 | $10.5M | New |
| SLDB Solid Biosciences Inc. | 0.77% | 1,860,542 | $10.5M | Reduce -2.0% |
| CBLL Ceribell Inc. | 0.70% | 435,239 | $9.5M | No change |
| ESTA Establishment Labs Holdings | 0.60% | 112,664 | $8.2M | Reduce -12.9% |
| ATRA Atara Biotherapeutics Inc. | 0.59% | 441,701 | $8.0M | No change |
| CLDX Celldex Therapeutics Inc. | 0.57% | 283,308 | $7.7M | Reduce -13.4% |
| LIVN Livanova PLC | 0.53% | 118,054 | $7.3M | Reduce -87.3% |
| IVVD Invivyd Inc. | 0.49% | 2,681,159 | $6.6M | Add +17.3% |
| XENE Xenon Pharmaceuticals Inc. | 0.44% | 133,882 | $6.0M | New |
| RPTX Repare Therapeutics Inc. | 0.30% | 1,586,174 | $4.1M | No change |
| ALXO Alx Oncology Holdings Inc. | 0.27% | 3,264,718 | $3.7M | Reduce -2.0% |
| ORIC Oric Pharmaceuticals Inc. | 0.27% | 448,110 | $3.7M | New |
| PLRX Pliant Therapeutics Inc. | 0.15% | 1,616,228 | $2.0M | Add +1.5% |
| KLRS Kalaris Therapeutics Inc. | 0.05% | 82,955 | $700K | No change |
Portfolio Sells Q3 2025 → Q4 2025
| ZYME Zymeworks Inc. | Reduce -86.7% | 0.95% | −5.20 |
| LIVN Livanova PLC | Reduce -87.3% | 0.53% | −4.19 |
| AKRO Akero Therapeutics Inc. | Sold out | 0.00% | −3.45 |
| ETNB 89BIO Inc. | Sold out | 0.00% | −2.11 |
| KROS Keros Therapeutics Inc. | Sold out | 0.00% | −0.85 |
| BEAM Beam Therapeutics Inc. | Reduce -7.3% | 2.62% | −0.65 |
| FOLD Amicus Therapeutics Inc. | Sold out | 0.00% | −0.60 |
| SLDB Solid Biosciences Inc. | Reduce -2.0% | 0.77% | −0.37 |
| XERS Xeris Biopharma Holdings Inc. | Sold out | 0.00% | −0.36 |
| VTYX Ventyx Biosciences Inc. | Sold out | 0.00% | −0.32 |
| ALXO Alx Oncology Holdings Inc. | Reduce -2.0% | 0.27% | −0.32 |
| LVTX Lava Therapeutics NV | Sold out | 0.00% | −0.31 |
| CLDX Celldex Therapeutics Inc. | Reduce -13.4% | 0.57% | −0.26 |
| STOK Stoke Therapeutics Inc. | Reduce -3.4% | 9.43% | −0.12 |
| PRME Prime Medicine Inc. | Sold out | 0.00% | −0.05 |
| BOLD Boundless Bio Inc. | Sold out | 0.00% | −0.03 |
| ESTA Establishment Labs Holdings | Reduce -12.9% | 0.60% | +0.09 |
| RGNX Regenxbio Inc. | Reduce -6.9% | 4.63% | +0.23 |
| COGT Cogent Biosciences Inc. | Reduce -34.9% | 3.76% | +0.67 |
Portfolio Buys Q3 2025 → Q4 2025
| NRIX Nurix Therapeutics Inc. | Add +120.0% | 11.31% | +8.00 |
| IMNM Immunome Inc. | Add +13.8% | 9.05% | +3.32 |
| SRRK Scholar Rock Holding Corp. | Add +33.7% | 16.94% | +2.79 |
| ANNX Annexon Inc. | Add +59.5% | 3.72% | +1.85 |
| NUVB Nuvation Bio Inc. | Add +4.4% | 2.09% | +1.00 |
| KRYS Krystal Biotech Inc. | Add +2.5% | 12.30% | +0.94 |
| RAPT Rapt Therapeutics Inc. | Add +60.3% | 2.21% | +0.82 |
| DBVT DBV Technologies SA-Spon ADR | New | 0.78% | +0.78 |
| REPL Replimune Group Inc. | Add +105.3% | 0.79% | +0.57 |
| XENE Xenon Pharmaceuticals Inc. | New | 0.44% | +0.44 |
| ORIC Oric Pharmaceuticals Inc. | New | 0.27% | +0.27 |
| IVVD Invivyd Inc. | Add +17.3% | 0.49% | +0.24 |
| NGNE Neurogene Inc. | Add +12.4% | 2.21% | +0.02 |
| PLRX Pliant Therapeutics Inc. | Add +1.5% | 0.15% | −0.08 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 39 | $1.5B | SRRK, KRYS, STOK, IMNM, NRIX |
| Q1 2026 | 35 | $1.5B | SRRK, KRYS, STOK, IMNM, NRIX |
| Q4 2025 | 34 | $1.4B | SRRK, KRYS, NRIX, STOK, IMNM |
| Q3 2025 | 40 | $1.0B | SRRK, KRYS, STOK, ZYME, ADCT |
| Q2 2025 | 48 | $939.6M | SRRK, KRYS, ZYME, STOK, IMNM |
| Q1 2025 | 56 | $1.1B | SRRK, KRYS, FOLD, ZYME, NRIX |
| Q4 2024 | 62 | $1.4B | SRRK, KRYS, NRIX, ZYME, FOLD |
| Q3 2024 | 63 | $1.7B | KRYS, NRIX, FOLD, IMNM, KYMR |
| Q2 2024 | 63 | $1.7B | KRYS, FOLD, NRIX, STOK, IMNM |
| Q1 2024 | 77 | $2.7B | KRYS, FOLD, IMNM, SRRK, FATE |